Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction.Circulation. 2006; 113: 1683-1692
- Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis.J Am Coll Cardiol. 1991; 18: 698-706
- Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation.Lancet. 1998; 352: 507-514
- A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective.J Am Coll Cardiol. 1999; 33: 1533-1539
- Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK).Eur Heart J. 2000; 21: 1450-1457
- Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort.Eur Heart J. 2005; 26: 18-26
- The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004.Eur Heart J. 2006; 27: 2285-2293
- Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.J Am Coll Cardiol. 2010; 56: 254-263
- Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).BMJ. 2006; 333: 1094
- Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG)™ acute myocardial infarction mortality model and risk score.Am Heart J. 2011; 161: 113-122
- Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK).Eur Heart J. 2004; 25: 2013-2018
- Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: The CRUSADE long-term mortality model and risk score.Am Heart J. 2011; 162: 875-883
- Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome.Am Heart J. 2007; 153: 29-35
- Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).Eur Heart J. 2010; 31: 2755-2764
- Recent trends in post-discharge mortality among patients with an initial acute myocardial infarction.Am J Cardiol. 2012; 110: 1073-1077
- Predictors of hospital mortality in the Global Registry of Acute Coronary Events.Arch Intern Med. 2003; 163: 2345-2353
- A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry.JAMA. 2004; 291: 2727-2733
- Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes.Am Heart J. 2001; 141: 190-199
- Decline in rates of death and heart failure in acute coronary syndromes, 1999 to 2006.JAMA. 2007; 297: 1892-1900
- The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE.Heart. 2010; 96: 1095-1101
- TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.Eur Heart J. 2005; 26: 865-872
- Validity of the GRACE (Global Registry of Acute Coronary Events) acute coronary syndrome prediction model for six month post-discharge death in an independent data set.Heart. 2006; 92: 905-909
- Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better.Eur Heart J. 2007; 28: 1072-1078
- The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide.Heart. 2011; 97: 1479-1483
- Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]).Am J Cardiol. 2004; 93: 288-293
- Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry.Nat Clin Pract. 2008; 5: 580-589
- The TIMI risk score for unstable angina/non-ST elevation MI - A method for prognostication and therapeutic decision making.JAMA. 2000; 284: 835-842
- TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation – an intravenous nPA for treatment of infarcting myocardium early II trial substudy.Circulation. 2000; 102: 2031-2037
- Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients.Circulation. 2000; 101: 2557-2567
- Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model.Heart. 2009; 95: 662-668
- Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events.Am Heart J. 2009; 157: 1097-1105
Funding: GRACE was supported by an unrestricted grant from Sanofi-Aventis (Paris, France) to the Center for Outcomes Research, University of Massachusetts Medical School. The sponsor had no involvement in the conception or design; collection, analysis, and interpretation of data; in the writing, review, or approval of the manuscript; and in the decision to submit the manuscript for publication.
Conflicts of Interest: SMAA, WH, and EF: None. JMG, PGS, KAE, FAA, KAAF, EG, DB, WK, FVW, AA, GM, DCG, AB, JL-S, CBG, BMK, RJG, and SGG: Research grant support, consulting honoraria from Sanofi Aventis. In addition, DCG reports speaker/consulting honoraria from Daiichi Sankyo, Bayer, Boehringer Ingelheim, Pfizer, Astra Zeneca and Eli Lilly; FAA reports research grants from The Medicines Company, and consulting honoraria from GlaxoSmithKline and Millennium; FVW reports speaker/consulting honoraria from AstraZeneca and The Medicines Company.
Authorship: All authors had access to the data and a role in writing the manuscript.